Results 1 to 10 of about 21,696 (215)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

Therapeutics and Clinical Risk Management, 2012
Alen Ostojic1, Radovan Vrhovac1, Srdan Verstovsek21Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 2Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX ...
Ostojic A, Vrhovac R, Verstovsek S
doaj   +1 more source

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Blood Advances
: Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic response. ADORE was
David M. Ross, Florian H. Heidel, Andrew Charles Perkins, Andreas Reiter, Carl Crodel, Caroline Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Jagannath Kota, Anirudh Prahallad, Monika Wroclawska, Min Lu, Claire N. Harrison   +22 more
doaj   +1 more source

Prevention of Irreversible Autoimmune Endocrinopathies in APECED with Ruxolitinib

Journal of Human Immunity
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED/APS-1) is a monogenic disorder of failed central tolerance caused by deleterious variants in the autoimmune regulator (AIRE) gene. Interferon-γ-driven inflammation in APECED underlies
Joseph Pechacek, Taura Webb, Lucas dos Santos Dias, Rachel Wu, Heather Moorman, Princess Barber, Lindsey Rosen, Benjamin Colton, Herodes Guzman, Maria Sacta, Shana McCormack, Aaron Bennett, Kathleen Loomes, Neil Romberg, Niamh McGrath, Steven Holland, Theo Heller, Karen Winer, Stefania Pittaluga, Michail Lionakis   +19 more
doaj   +1 more source

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica, 2013
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian   +22 more
doaj   +1 more source

Ruxolitinib treatment in patients with polycythemia vera reduces variant allele frequency and improves symptom burden and hematocrit control

Therapeutic Advances in Hematology
Background: In RESPONSE/RESPONSE-2, ruxolitinib was superior to best available therapy (BAT) in patients with polycythemia vera (PV). Objective: Report a post hoc pooled RESPONSE/RESPONSE-2 analysis.
Claire N. Harrison, Jean-Jacques Kiladjian, J. E. Hamer-Maansson, Ahmad Naim, Francesca Palandri, Francesco Passamonti   +5 more
doaj   +1 more source

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review

Frontiers in Oncology
Myelofibrosis (MF) is a philadelphia chromosome-negative chronic myeloprolifera- tive neoplasm.It has a worse prognosis than polycythemia vera and essential thrombocy- themia.At present,both Chinese and foreign guidelines recommend ruxolitinib as first ...
Xiaohong Liu, Xiujuan Zhang, Hongxia Shi
doaj   +1 more source

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era

Haematologica
The recent progress with ruxolitinib treatment might improve quality-of-life as well as overall survival in patients with primary myelofibrosis (PMF).
Yosuke Okada, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Kazuki Yoshimura, Masaharu Tamaki, Akari Matsuoka, Takuto Ishikawa, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Machiko Kusuda, Aki Tanihara, Shun-ichi Kimura, Shinichi Kako, Yoshinobu Kanda   +18 more
doaj   +1 more source

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica, 2015
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies.
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek   +14 more
doaj   +1 more source

Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary

Therapeutic Advances in Hematology
Summary What is this summary about? Ruxolitinib (JAKAFI ® ) is a Janus kinase (JAK) 1 and JAK2 inhibitor that is approved for acute and chronic graft-versus-host disease (GVHD).
Zahra Mahmoudjafari, Valkal Bhatt, Zhenyi Xue, Franco Locatelli, Gérard Socié, Robert Zeiser   +5 more
doaj   +1 more source

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial

Journal of Dermatological Treatment
Purpose Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).Materials and methods Patients aged 12–70 years with AD (Investigator’s Global ...
Zelma C. Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar   +4 more
doaj   +1 more source